Tau-targeting programs advance behind the amyloid wave

While anti-amyloid therapies dominate current rollout discussions, tau-directed programs are quietly advancing. The biological rationale is well-established: tau pathology correlates more closely with cognitive decline than amyloid burden does, and tau spread tracks the clinical progression of the disease.

The current pipeline spans several mechanistic approaches:

• Anti-tau monoclonal antibodies targeting extracellular tau species, with the goal of interrupting trans-synaptic spread.
• Antisense oligonucleotides designed to reduce tau production directly, delivered intrathecally.
• Small-molecule aggregation inhibitors and active immunotherapies at earlier stages.

Several programs that disappointed in earlier trials have been redesigned with refined patient selection - typically using tau PET to enrich for participants with measurable pathology and room to show change.

Two questions will define the next eighteen months:

• Whether any anti-tau program produces a clinical signal that survives statistical scrutiny in a registration-enabling trial.
• How tau and amyloid therapies will be sequenced or combined, given that they target different stages of the same disease cascade.

A positive tau readout would meaningfully expand the disease-modification toolkit. A negative one would reinforce the operational reality that amyloid-targeting antibodies remain the only disease-modifying option for the foreseeable future.

A positive readout would also immediately expose a separate access question: tau PET availability and reimbursement, which gate who actually gets treated. We cover that in our Signal on tau PET as the next diagnostic access question.